This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Stevenson, L. W. Articles by Creaser, J. W. Search for Related Content PubMed Articles by Stevenson, L. W. Articles by Creaser, J. W.

(Circulation. 1995;92:174-181.)
© 1995 American Heart Association, Inc.

Articles

Target Heart Failure Populations for Newer Therapies

Lynne Warner Stevenson, MD; Gregory Couper, MD; Barbara Natterson, MD; Gregg Fonarow, MD; Michele A. Hamilton, MD; Mary Woo, DScN; Julie W. Creaser, MS, RN

From the Divisions of Cardiology and Cardiothoracic Surgery, Brigham and Women's Hospital, Boston, Mass, and the University of California, Los Angeles.

Correspondence to Lynne Warner Stevenson, MD, Cardiovascular Division, Brigham and Women's Hospital, 75 Francis St, Boston, MA 02115.

Background The scarcity of donor hearts has created a large population of heart failure patients who are unlikely to undergo transplantation. Newer surgical therapies that might sustain such patients at home previously have been applied in critical situations in which early outcome is jeopardized by multiorgan failure. The optimal population for studies of extended support would be ambulatory patients with low operative risk but high risk of later unfavorable outcome.

Methods and Results Baseline clinical, echocardiographic, and hemodynamic data were collected prospectively between 1988 and 1993 in 500 patients who were discharged on tailored medical therapy after evaluation for transplantation. Specific criteria were examined to identify high risk of death or need for urgent transplantation during the next 2 years. In 265 patients with ejection fraction 25% and initial New York Heart Association class IV symptoms, survival at 2 years was 55% (without urgent transplantation, 45%). Lower cardiac index or higher filling pressures at the time of referral did not confer higher risk, which was predicted by persistence of higher pressures after therapy. Serum sodium below 133 was associated with 34% 2-year survival without urgent transplantation, and ventricular dimension >80 mm with a rate of 25%. Patients with initial peak oxygen consumption >10 mL/kg per minute had a 2-year event-free rate of 72% compared with 48% for those with <10 mL/kg per minute and 32% for those unable to exercise at referral. Demonstration of a 30% decrease in mortality with a controlled trial of new therapy in patients with ejection fraction 25% would require 600 patients with class III symptoms or almost 300 patients with class IV symptoms unless another criterion were added.

Conclusions Ambulatory populations with high predicted event rates can be identified at initial evaluation, when hemodynamic criteria may be less useful than ventricular dimension, serum sodium, and ability to exercise. The use of outcome data from previous eras may lead to overestimation of benefits from newer therapies and underestimation of the sample size required in a prospective trials.

Key Words: cardiomyopathy • transplantation • heart failure

This article has been cited by other articles:

				L. W. Stevenson Patient Selection for Mechanical Bridging to Transplantation Ann. Thorac. Surg., January 1, 1996; 61(1): 380 - 387. [Abstract] [Full Text]